Insmed shelves Brinsupri in skin disease after mid-stage flop
Elizabeth Cairns / endpoints - Insmed has given up on Brinsupri in the painful skin disorder hidradenitis suppurativa (HS) after a mid-stage trial failure. The company had ditched the pill in sinus inflammation at the end of last year. The ...
AI Summary: Insmed announced it will halt development of Brinsupri for a dermatologic indication following disappointing mid‑stage trial results. Company commentary stressed the skin setback does not negate Brinsupri’s potential in pulmonary indications, but investors and clinicians will understandably ask for clearer signs of life before buying the comeback story.
Related Stories
BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 7 wks
FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 3 months
First-in-human trial primes immune system to accept donor livers / 2 months
Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 2 months
Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 1 month
Avalyn upsizes IPO to raise cash for lung drug trials / 2 months
Drug-induced hibernation shows promise to limit stroke brain injury / 21 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Clinical Trials, Autism, Olfaction, Long COVID and look for the RSS link.
StackHealth Time Machine